Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 2Papillomavirus Infections 1Hepatitis C, Chronic 1Fibrosis 1Condylomata Acuminata 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 29Papillomavirus Vaccines 22Vaccines 11Human Papillomavirus Recombinant Vaccine nonavalent 11Radiotherapy, Intensity-Modulated 7Human Papillomavirus DNA Tests 7Colposcopy 7Cisplatin 7Educational Status 6Carboplatin 6Blood Specimen Collection 6Vaccines, Synthetic 5Specimen Handling 5Early Intervention, Educational 5Vaginal Smears 4Methods 4Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Surveys and Questionnaires 3Patient Navigation 3Paclitaxel 3Imiquimod 3Hepatitis A Vaccines 3Cyclophosphamide 3halofantrine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Papillomavirus Infections × Viusid × Clear all
NCT03584308 2019-05-22

Efficacy of VIUSIDĀ® Plus GLIZIGENĀ® in Patients With Papilloma Virus Esophageal

Catalysis SL

Phase 2 Completed
110 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚔